|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Case | GA (wk) | Fetal sex | cfDNA result | Deletion size | Confirmatory Genetic Testing | Pregnancy Outcome (GA (wk)) | SGA | Echocardio-gram | Evaluation for hypocalcemia | Lymphocyte Count |
| 1 | 21 | M | HR | A-D | Study microarray only | LB term  Discharged first week | No | NC | NC | NC |
| 2 | 32 | F | HR | A-D | Clinical, Postnatal | LB late preterm  Discharged second month of life | Yes | Prenatal Abnormal  Postnatal Abnormal  Cardiac surgery | Hypocalcemia  Calcium administered | Normal§ |
| 3 | 10 | M | HR | A-D | Study microarray only | LB term  Discharged first week | No | Prenatal Normal  Postnatal NR | NR | NR |
| 4 | 18 | F | HR | A-D | Clinical, Postnatal | LB late preterm  Discharged to chronic care facility second month of life | No | Prenatal Abnormal  Postnatal Abnormal  Cardiac surgery | Hypocalcemia  No documented calcium administration | Normal§ |
| 5 | 10 | F | HR | Minimum A-B† | Clinical, Prenatal | TAB second trimester | NA | Prenatal Abnormal  Postnatal NR | NR | NR |
| 6 | 12 | M | HR | Minimum A-B† | Clinical, Prenatal | TAB second trimester | NA | Prenatal NR  Postnatal NR | NR | NR |
| 7 | 22 | F | HR | Minimum A-B† | Study microarray only | LB term  death first week | Yes | Prenatal NR  Postnatal NR | NR | NR |
| 8 | 10 | F | HR | A-C  2.0 Mb atypical | Clinical, Prenatal | TAB – time unknown | NA | Prenatal Abnormal Postnatal NC | NC | NC |
| 9 | 21 | F | HR | A-B  1.4-1.5 Mb | Clinical, Postnatal | LB term  Discharged third week | No | Prenatal Normal  Postnatal Abnormal | Hypocalcemia  Calcium administered | Normal§ |
| 10 | 12 | F | LR | A-B  1.4-1.5 Mb | Study microarray only | LB term  Discharged first week | No | NC | NC | NC |
| 11 | 15 | F | LR | B-D  0.73 Mb | Study microarray only | LB term  Discharged first week | No | NC | NC | NC |
| 12 | 13 | M | LR | B-D  0.73 Mb | Study microarray only | LB term  Discharged first week | Yes | NC | NC | NC |

**Supplement 2**

**Supplementary Table 1**. Selected outcomes for SMART study pregnancies confirmed affected with 22q11.2DS

GA, gestational age; wk, week; MA, maternal age; SGA, small for gestational age; HR, high-risk; LR, low-risk; LB, live birth; TAB, therapeutic abortion; NC, supplemental data form not completed; NR, Supplemental data form completed; testing not recorded. †Deletion size determined by FISH/Bacs on beads with probes in the A-B region. §Normal lymphocyte ranges 2.07-7.53 x 109 /L for males and 1.75-8.00 x 109 /L for females.1 Case numbers in this table are aligned with those in Table 2 in Dar et al. 2022.2

**References:**

1. Grosse SD, Khoury MJ. What is the clinical utility of genetic testing? *Genet Med.* 2006;8(7):448-450.
2. Dar P, Jacobsson B, Clifton R, et al. Cell-free DNA screening for prenatal detection of 22q11.2 deletion syndrome. *Am J Obstet Gynecol.* 2022.